Clinical Trials

Clinical Trials

The mission of our clinical trials is to allow patients in Northern Nevada with kidney associated conditions to have access to the most advanced and cutting edge treatments and technologies for their conditions.

Sierra Nevada Nephrology is actively involved in many clinical research trials. We focus on clinical trials that are attempting to improve the care of chronic kidney disease, hypertension, genetic renal disease, anemia, gout, anemia, electrolyte abnormalities, and a variety of other conditions associated with kidney care. We believe any, and all, patients with advanced chronic diseases, including kidney disease, should have access to the most recent and advanced care strategies and medications available.

Our team of dedicated research nurses and physicians have many years of experience caring for and monitoring patients in clinical trials. We work in concert with local labs and imaging centers to administer the trials, limiting the burden of travel and inconvenience.

 

Active Studies:


Active; Not Enrolling

Name: Duplex Study-Retrophin
Title: To assess the safety and tolerability of sparsentan and to determine the long-term nephroprotective potential of treatment with sparsentan compared to an angiotensin receptor blocker in patients with primary focal segmental glomerulosclerosis (FSGS).
Trial Info: https://clinicaltrials.gov/ct2/show/NCT03493685?term=sparsentan&cond=focal+segmental+glomerulosclerosis&cntry=US&state=US%3ANV&draw=2&rank=1https://www.fsgsduplex.com/#!/

Name: Normalize-Ardelyx
Title: A long term, open label study to evaluate the ability of tenapanor alone or in combination with Sevelamer to treat goal serum phosphorus in patients with end-stage-renal disease on dialysis (ESRD).
Trial Info: https://clinicaltrials.gov/ct2/show/NCT03988920?term=tenapanor&cond=Hyperphosphatemia&cntry=US&draw=2&rank=2

 

Active; Currently Screening

Name: Protect-Retrophin
Title: To assess the safety and tolerability of sparsentan and to determine the effect of sparsentan on proteinuria and renal function, as compared to angiotensin receptor blocker, in patients with Immunoglobulin A Nephropathy (IgAN).
Trial Info: https://clinicaltrials.gov/ct2/show/NCT03762850?term=sparsentan&cond=Immunoglobulin+A+Nephropathy&cntry=US&state=US%3ANV&draw=2&rank=1http://www.retrophin.com/content/pipeline/sparsentan.php

Name: Calciphyx-Sanifit Therapeutics S.A.
Title: To Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis.
Trial Info: https://www.clinicaltrials.gov/ct2/show/NCT04195906?cond=Calciphylaxis&draw=2&rank=5

If you feel you may be a good fit for one of these trials, please let your care providers know.

 

START TYPING AND PRESS ENTER TO SEARCH